Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth

[Image: see text] With the emergence of multi-drug-resistant strains of Mycobacterium tuberculosis, there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti-tubercular in vitro activity have been identified from phenotypic screening that app...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:ACS Omega
Main Authors: Ray, Peter C., Huggett, Margaret, Turner, Penelope A., Taylor, Malcolm, Cleghorn, Laura A. T., Early, Julie, Kumar, Anuradha, Bonnett, Shilah A., Flint, Lindsay, Joerss, Douglas, Johnson, James, Korkegian, Aaron, Mullen, Steven, Moure, Abraham L., Davis, Susan H., Murugesan, Dinakaran, Mathieson, Michael, Caldwell, Nicola, Engelhart, Curtis A., Schnappinger, Dirk, Epemolu, Ola, Zuccotto, Fabio, Riley, Jennifer, Scullion, Paul, Stojanovski, Laste, Massoudi, Lisa, Robertson, Gregory T., Lenaerts, Anne J., Freiberg, Gail, Kempf, Dale J., Masquelin, Thierry, Hipskind, Philip A., Odingo, Joshua, Read, Kevin D., Green, Simon R., Wyatt, Paul G., Parish, Tanya
Formato: Artigo
Idioma:Inglês
Publicado: American Chemical Society 2021
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841955/
https://ncbi.nlm.nih.gov/pubmed/33521468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c05589
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares